| 名称 | PF-04929113 Mesylate |
| 描述 | PF-04929113 Mesylate (SNX-5422 Mesylate), a prodrug of SNX-2112, is an orally available Hsp90 inhibitor (Kd: 41 nM) and also induces Her-2 degradation (IC50: 37 nM). |
| 细胞实验 | PF-04929113 is dissolved in DMSO.Cell viability is determined by the CCK-8 Assay Kit. Cells (5 × 103/100 μL) in each well on 96-well plates are incubated overnight and treated with the drugs (PF-04929113) for an additional 4 h at 37°C. Absorbance is measured at 450 nm using a spectrophotometer. |
| 激酶实验 | Briefly, Hsp90 from porcine spleen extract is isolated by affinity capture on a purine-affinity media. The Hsp90 loaded media is then challenged with test compound (PF-04929113) at a given concentration, ranging from 0.8 to 500 μM, and the amount of Hsp90 liberated at each concentration is determined. The resulting IC50 values are corrected for the ATP ligand concentration and presented as apparent Kd values. |
| 动物实验 | PF-04929113 is preformulated in 1% microcrystalline cellulose/0.5% Tween80 in water.Female nude mice are 11 to 12 weeks old and have a body weight range of 18.7?30.5 g on Day 1 of the study. Xenografts are initiated from HT-29 human colon carcinoma tumors maintained by serial transplantation in athymic nude mice. Each test mouse receives a 1 mm3 HT-29 tumor fragment implanted subcutaneously in the right flank, and the growth of tumors is monitored as the average size approached 80?120 mm3. Fourteen days later, designated as Day 1 of the study, individual tumor volumes range from 63 to 126 mm3 and the animals are placed into eight groups, each consisting of 10 mice with group mean tumor volumes of 93.2?93.9 mm3. Micronized PF-04929113 is preformulated in 1% microcrystalline cellulose/0.5% Tween80 in water. The solutions are stored at 4°C during the study and homogenized just prior to dosing. Group 1 vehicle control mice receive D5W (5% dextrose) vehicle by oral gavage beginning on Day 1, every other day for three doses, followed by two days without treatment, for three cycles ((qod × 3)/2 × 3 weeks, a total of nine doses). Groups 2 to 5 animals receive 10 at 5, 10, 25, or 50 mg/kg on the same schedule as vehicle control group ((qod × 3)/2 × 3). Each treatment is administered in a volume of 0.2 mL per 20 g of body weight (10 mL/kg) and is scaled to the body weight of the animal. Tumors are measured twice weekly using calipers. |
| 体外活性 | PF-04929113 在AU565细胞中有效抑制Her2（IC50：5±1 nM）和p-ERK稳定性（IC50：11±3 nM），抑制p-S6（IC50：61±22 nM）。同样，在A375细胞中，PF-04929113还能诱导Hsp70（IC50：13±3 nM）。PF-04929113（0.5、1、2、5及10 μM）浓度依赖性地降低细胞活力。此外，PF-04929113（1、3、5、7 μM）与HDAC抑制剂（PXD101、SAHA和TSA）等量组合，通过抑制PI3K/Akt/mTOR信号通路，协同诱导ATC细胞死亡。 |
| 体内活性 | 在HT-29人类结肠癌异种移植模型中，PF-04929113（50 mg/kg，p.o.）通过每周三次，持续三周的给药（qod × 3/2 × 3）后，强效抑制肿瘤生长。PF-04929113（20/40 mg/kg，p.o.）在小鼠中显著抑制多发性骨髓瘤（MM）的肿瘤血管生成和生长。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 27.5 mg/mL (44.52 mM)
|
| 关键字 | PF 04929113 Mesylate | PF-04929113 Mesylate | PF04929113 | SNX5422 Mesylate | PF-04929113 | PF 04929113 | PF04929113 Mesylate | SNX 5422 Mesylate |
| 相关产品 | Neratinib | Teprenone | SNX0723 | Afatinib Dimaleate | Tamoxifen Citrate | Rifabutin | Tucatinib | VU 0240551 | Paeoniflorin | Tamoxifen | Ethoxyquin | AG-1478 |
| 相关库 | 抑制剂库 | 抗乳腺癌化合物库 | 抗癌活性化合物库 | 经典已知活性库 | 已知活性化合物库 | 抗肺癌化合物库 | 药物功能重定位化合物库 | 酪氨酸激酶分子库 | 抗癌临床化合物库 | 抗癌药物库 |
